Catalog3 refs
ACE-031
OtherMuscle GrowthHormonalResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
MusclesCirculationSkin
Overview
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia.
Primary Uses
Muscle Hypertrophy
Muscular Dystrophy
Muscle Wasting / Cachexia
Fat Loss
Bone Density
Muscle growth and preservation
Duchenne muscular dystrophy
Increasing lean mass
Decreasing fat mass
Bone mineral density improvement
Protocol Reference
Dose
0.5-3 mg/kg every 2 weeks in trials
Frequency
Once weekly
Half-life
12-15 days
Route
Subcutaneous injection
Evidence
Preclinical / Emerging (disputed)
Research Models
Humananimal
Also in Other